Adrenal MRI Calculator for Chemical Shift
Related Calculators
Differentiation of adrenal adenomas using absolute and relative washout measurements on contrast-enhanced CT.
Thyroid nodule risk stratification using ultrasound features and ACR TI-RADS scoring system.
Liver lesion classification for hepatocellular carcinoma risk using CT, MRI, ultrasound, and contrast-enhanced ultrasound.
Liver volume estimation using imaging measurements with comparison to expected normal values.
More about the Adrenal MRI Chemical Shift Calculator
Adrenal incidentaloma evaluation and the role of adrenal chemical shift MRI
The Adrenal MRI Chemical Shift Calculator supports quantitative interpretation within the broader framework of adrenal chemical shift MRI, a well-established technique for adrenal lesion characterization. As adrenal incidentalomas are identified more frequently on cross-sectional imaging, radiologists are often asked to distinguish benign adenomas from metastases, adrenocortical carcinoma, pheochromocytoma, and other indeterminate adrenal masses. Chemical shift MRI helps by demonstrating signal behavior related to intracellular lipid, a characteristic feature of many adrenal adenomas, while the calculator provides a practical way to apply commonly reported quantitative metrics.[1][2][3]
Adrenal MRI is often most useful when unenhanced CT is not fully decisive, particularly in lesions with attenuation values above the classic lipid-rich threshold. Homogeneous adrenal lesions measuring 10 HU or less on noncontrast CT are generally considered benign and typically do not require further imaging, whereas lesions in the 11 to 20 HU range may remain indeterminate and warrant additional characterization depending on clinical context. In that setting, quantitative MRI can help standardize signal-based measurements and improve consistency when assessing whether a lesion demonstrates a lipid-rich adenoma pattern or remains indeterminate.[1][2][3]
Physics of adrenal chemical shift MRI
Chemical shift imaging is based on the difference in resonance frequency between protons in fat and protons in water. Because these proton populations precess at slightly different frequencies, their signals periodically align and oppose one another. Gradient-echo sequences exploit this behavior by acquiring images at echo times when water and fat are in phase or opposed phase, forming the basis for both qualitative assessment and the quantitative calculations used here.[1]
At 1.5 T, the water-fat frequency difference is approximately 220 Hz, producing typical opposed-phase and in-phase echo times near 2.2 ms and 4.4 ms, respectively. At 3.0 T, the frequency separation doubles, with shorter echo times. These technical parameters directly affect signal measurements, and incorrect timing can reduce the reliability of calculated indices.[1][4]
Within a voxel that contains both water and microscopic fat, the signal partially cancels on opposed-phase images. In adrenal imaging, this signal drop reflects intracellular lipid and underlies both visual assessment and quantitative measurements such as the signal intensity index.[1][2]
Technique details that affect measurement accuracy
Paired in-phase and opposed-phase images should be obtained with consistent slice position and during the same breath-hold whenever possible. Misregistration between acquisitions can create false differences in measured signal intensity. Early opposed-phase acquisition also helps reduce T2* effects that can mimic true fat-related signal loss.[1]
Why adrenal adenomas lose signal on opposed-phase imaging
The adrenal cortex normally contains intracellular lipid, and many benign cortical adenomas retain this property. As a result, adrenal adenomas often show reduced signal on opposed-phase images. Lipid-rich adenomas typically show clear signal loss and often meet reported quantitative thresholds.[1][2]
Not all adenomas are markedly lipid-rich. A lipid-poor adenoma may show only mild signal loss or remain indeterminate visually. Quantitative assessment can help identify subtle differences in signal intensity, although some lesions still remain indeterminate despite measurement.[1][2]
Most non-adenomatous adrenal lesions do not contain sufficient intracellular lipid to produce meaningful signal loss. However, overlap exists, and certain metastases may demonstrate partial signal drop, particularly metastases from clear cell renal cell carcinoma or hepatocellular carcinoma, which can contain intracellular lipid. These findings should therefore be interpreted with morphology, clinical history, and the overall imaging context.[1]
| Parameter | 1.5 T | 3.0 T | Clinical note |
|---|---|---|---|
| Opposed-phase echo time | Approximately 2.2 ms | Approximately 1.1 ms | Affects signal measurement used in calculations |
| In-phase echo time | Approximately 4.4 ms | Approximately 2.2 ms | Used as reference for calculator inputs |
| Adrenal signal intensity index formula | [(Adrenal SI in-phase - Adrenal SI opposed-phase) / Adrenal SI in-phase] x 100 | Primary calculation used in the adrenal MRI chemical shift calculator | |
| Adrenal signal intensity index threshold | >16.5% | >1.7% | Reported values that may support lipid-rich adenoma interpretation depending on technique[1][4] |
| Adrenal-to-spleen ratio formula | [((Adrenal SI opposed-phase / Spleen SI opposed-phase) / (Adrenal SI in-phase / Spleen SI in-phase)) - 1] x 100 | Alternative calculation available in the calculator | |
| Adrenal-to-spleen ratio threshold | ≤-35.9% | ≤-17.2% | Reported thresholds that may favor adenoma in appropriate context[1][4] |
Quantitative interpretation
While many adenomas can be recognized visually, quantitative assessment provides a standardized way to measure signal loss. The most commonly used outputs are the adrenal signal intensity index and the adrenal-to-spleen ratio, both of which translate visible signal differences into measurable values that can support structured interpretation.[1]
Adrenal signal intensity index
The adrenal signal intensity index represents the percentage signal loss from in-phase to opposed-phase imaging. Higher values reflect greater intracellular lipid content. Results should always be interpreted in the context of technique and image quality.[1]
Adrenal-to-spleen ratio
The adrenal-to-spleen ratio compares adrenal signal with splenic signal across sequences and provides an internal reference-based assessment. Its reliability depends on stable splenic signal and consistent acquisition technique. The measurement may be less reliable in the presence of splenic iron deposition, susceptibility effects, or other factors that alter splenic signal intensity.[1]
Protocol considerations and clinical interpretation
Protocol design directly affects the reliability of calculated values. Consistent acquisition technique, appropriate echo times, and careful ROI placement are essential. Differences in sequence design, including dual gradient-echo versus Dixon techniques, may influence measured signal loss and the final calculated outputs.[4]
For longitudinal comparison or consistent reporting, the same acquisition method should be used. Quantitative results are most useful in indeterminate adrenal lesions where visual assessment alone is insufficient. If a lesion demonstrates significant signal loss and appropriate imaging features, the findings may support the presence of intracellular lipid and favor an adenoma in the appropriate clinical context.[1]
These results should be integrated with imaging appearance, clinical history, and guideline-based evaluation pathways. Imaging thresholds are supportive rather than definitive, and further evaluation may still be required depending on the clinical scenario.[3]
Pitfalls and limitations of calculator-based assessment
Quantitative outputs from the Adrenal MRI Chemical Shift Calculator are influenced by technical factors such as motion, misregistration, susceptibility effects, and ROI placement. Small lesions are particularly susceptible to variability, which may affect measurement reliability.[1]
False positives and false negatives can occur. Some malignant lesions may show partial signal loss, particularly in the setting of intracellular lipid, while some adenomas may not demonstrate sufficient measurable change. These overlaps highlight the importance of interpreting quantitative results in conjunction with the full imaging and clinical context.[1][2]
Integration with clinical context, prior imaging, and biochemical evaluation remains essential for comprehensive assessment.[3]
Frequently Asked Questions (FAQs)
How does adrenal chemical shift MRI help distinguish adenoma from metastasis?
Adrenal chemical shift MRI detects intracellular lipid. Many adenomas contain microscopic fat and show signal loss on opposed-phase images, whereas many metastases do not. Findings should still be interpreted in conjunction with clinical history and other imaging features.[1][2]
What causes signal drop on out-of-phase images in an adrenal lesion?
Signal drop occurs when fat and water coexist within the same voxel. On opposed-phase imaging, their signals partially cancel, resulting in decreased signal intensity. This reflects intracellular lipid in many adrenal adenomas.[1]
What is the signal intensity index for adrenal lesions?
The signal intensity index is calculated as [(SI in-phase - SI opposed-phase) / SI in-phase] x 100. At 1.5 T, values greater than 16.5% may support a lipid-rich adenoma, although interpretation depends on technique and clinical context.[1][4]
When is MRI more useful than CT for adrenal incidentaloma evaluation?
MRI is particularly useful when unenhanced CT findings are indeterminate, especially for lesions with intermediate attenuation. Chemical shift MRI can demonstrate intracellular lipid without ionizing radiation and may improve lesion characterization.[2][3]
What are the main limitations of adrenal chemical shift MRI?
Limitations include overlap with lipid-containing malignancies, reduced sensitivity for lipid-poor adenomas, technical artifacts, and reduced reliability of reference-based measurements when splenic signal is altered by iron deposition or susceptibility effects.[1]
References
- Adam SZ, Nikolaidis P, Horowitz JM, et al. Chemical shift MR imaging of the adrenal gland: principles, pitfalls, and applications. Radiographics. 2016;36(2):414-432. doi:10.1148/rg.2016150139. https://doi.org/10.1148/rg.2016150139
- Platzek I, Sieron D, Plodeck V, et al. Chemical shift imaging for evaluation of adrenal masses: a systematic review and meta-analysis. Eur Radiol. 2019;29(2):806-817. doi:10.1007/s00330-018-5626-5. https://doi.org/10.1007/s00330-018-5626-5
- Fassnacht M, Tsagarakis S, Terzolo M, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas. Eur J Endocrinol. 2023;189(1):G1-G42. doi:10.1093/ejendo/lvad066. https://doi.org/10.1093/ejendo/lvad066
- Khan AS, Carney BW, Corwin MT. Detection of microscopic fat in adrenal adenomas: comparison of 2D dual gradient-echo MRI and 3D two-point Dixon techniques. Acta Radiol. 2025;66(11):1202-1207. doi:10.1177/02841851251358865. https://doi.org/10.1177/02841851251358865
PGY-5 Radiology and Nuclear Medicine Resident Physician
UT Southwestern Medical Center, USA
